STANDARD TREATMENT WITH BEVACIZUMAB AS TARGETED THERAPY IN CERVICAL CANCER

被引：0

作者：

Enriquez-Aceves, Isabel ^{[1
]}

Galicia-Carmona, Tatiana ^{[2
,3
]}

Coronel-Martinez, Jaime A. ^{[2
,3
]}

Espinosa-Romero, Raquel ^{[3
]}

Calderillo-Ruiz, German ^{[3
]}

Cortes-Esteban, Patricia ^{[4
]}

Cetina-Perez, Lucely ^{[2
,3
]}

机构：

[1] Hosp Inst Seguridad & Serv Sociales Trabajadores, Dept Med Oncol, Leon, Gto, Mexico

[2] Inst Nacl Cancerol, Dept Clin Res, Mexico City, DF, Mexico

[3] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico

[4] Ctr Med Nacl 20 Noviembre, Dept Med Oncol, Mexico City, DF, Mexico

来源：

REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2020年 / 72卷 / 04期

关键词：

Bevacizumab; Cervical; Cancer; Metastatic antiangiogenic; PHASE-II TRIAL; SQUAMOUS-CELL-CARCINOMA; COMBINATION THERAPY; 3RD-LINE TREATMENT; OPEN-LABEL; RECURRENT; PERSISTENT; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL;

D O I：

10.24875/RIC.20000061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metastatic, recurrent, or persistent disease in cervical cancer has a poor prognosis. Historically, this group of patients has had limited treatment options, even with the best cytotoxic treatments (platinum-based chemotherapy [CT] doublets). Therefore, investigating new medications that help improve the patient's quality of life and survival has been essential. Angiogenesis has been shown to play a critical role in tumor cell growth and survival. Bevacizumab is a recombinant humanized monoclonal G1 immunoglobulin targeted against vascular endothelial growth factor. The combination of CT and bevacizumab is associated with an increase in overall survival as well as in progression-free survival and response rates.

引用

页码：213 / 218

页数：6

共 50 条

[31] Biologics in Cervical Cancer Therapy
Willmott, Lyndsay J.
Sumner, Daniele A.
Monk, Bradley J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (12): : 1417 - 1423
[32] Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement
Girda, Eugenia
Randall, Leslie M.
Chino, Fumiko
Monk, Bradley J.
Farley, John H.
O'Cearbhaill, Roisin E.
GYNECOLOGIC ONCOLOGY, 2023, 179 : 115 - 122
[33] Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer
Tan, S. J.
Juan, Y. H.
Fu, P. T.
Yu, M. H.
Lai, H. C.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 31 (03) : 350 - 353
[34] Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
Kishigami, Yasuyuki
Kondo, Eiji
Yamawaki, Takaharu
Nagao, Kenji
Hirata, Toru
Kotaka, Saki
Kondo, Eiji
Kawai, Yosuke
Okamoto, Kota
Suzuki, Shiro
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (05)
[35] Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence
Jackson, Matthew W.
Rusthoven, Chad G.
Fisher, Christine M.
Schefter, Tracey E.
ONCOTARGETS AND THERAPY, 2014, 7 : 751 - 759
[36] Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, Krishnansu S.
Sill, Michael W.
Long, Harry J., III
Penson, Richard T.
Huang, Helen
Ramondetta, Lois M.
Landrum, Lisa M.
Oaknin, Ana
Reid, Thomas J.
Leitao, Mario M.
Michael, Helen E.
Monk, Bradley J.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (08) : 734 - 743
[37] Outcomes and toxicities for the treatment of stage IVB cervical cancer
Hwang, Jong Ha
Lim, Myong Cheol
Seo, Sang-Soo
Kang, Sokbom
Park, Sang-Yoon
Kim, Joo-Young
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2012, 285 (06) : 1685 - 1693
[38] Bevacizumab in breast cancer: a targeted therapy still in search of a target population
Marks, Douglas K.
Kalinsky, Kevin
SEMINARS IN ONCOLOGY, 2017, 44 (04) : 286 - 287
[39] Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
Georgios V. Koukourakis
Anastasia Sotiropoulou-Lontou
Clinical and Translational Oncology, 2011, 13 : 710 - 714
[40] Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer
Koukourakis, Georgios V.
Sotiropoulou-Lontou, Anastasia
CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (10) : 710 - 714

← 1 2 3 4 5 →